Abstract:Background: Irritable bowel syndrome (IBS) is a commonly seen chronic functional bowel disorder that severely affects the quality of life of patients.However,the efficacy of drugs now used for treating IBS is largely unsatisfactory.Aims: To investigate the efficacy and safety of drotaverine hydrochloride for the treatment of IBS.Methods: A prospective,self-control, multicentre clinical trial was performed.Two hundred and seventeen IBS patients were enrolled and treated with oral drotaverine hydrochloride tablets 80 mg three times a day for 2 weeks.The abdominal pain,feeling of incomplete defecation,straining and urgency,as well as the stool frequency and stool form were recorded daily.Results: Compared with those before treatment,the average weekly score for abdominal pain in IBS patients was significantly decreased (0.66± 0.59 vs.1.42±0.42,P=0.0000),and the overall efficacy rate was 77.9%; the average daily stool frequency was significantly increased in IBS with constipation (IBS-C) group (0.8±0.3 vs.0.6±0.4,P=0.0004),while significantly decreased in IBS with diarrhea (IBS-D) group (1.6±0.8 vs.2.8±1.2,P=0.0000).Stool form and feeling of incomplete defecation,straining and urgency in both groups were improved in different extents.No severe adverse events were observed.Conclusions: Drotaverine hydrochloride is effective and safe in treating all subtypes of IBS.

Treatment of Irritable Bowel Syndrome with Drotaverine Hydrochloride: A Multicentre Clinical Trial